Thomas J Prior

6PUBLICATIONS
41CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMedical mycologyPredictive and prognostic markersMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 02, 2026
Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

|Sep 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Ajai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria

|Mar 27, 2025
Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential.

Walter M Gregory, Thomas J Prior, J Blake Bartlett

|Feb 12, 2025
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.

Qian Shi, Bruno Paiva, Levi D Pederson

|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.

Ola Landgren, Thomas J Prior, Tara Masterson

|Jun 12, 2020
Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.

Thomas J Prior

Pageof 1

Frequent Collaborators

3 joint publications

Hartmut Goldschmidt

2 joint publications

Paula Rodriguez-Otero

2 joint publications

Laura Rosiñol

2 joint publications

Manisha Bhutani